No Current Drug Has Proved It Can Slow Hip Wear

A cartilage change may not ease your soreness

An X-ray can show changes inside a joint. It can't tell you whether dressing or sleeping became easier. Drug research has found that those results don't always agree. More cartilage on an image doesn't always mean less soreness.

This matters when you hear a claim about rebuilding a joint. Ask whether people also walked or slept with less trouble. If they didn't feel better, the image change offers little help today. Your concern is what the treatment could change in daily life.

Current care aims to ease soreness and keep you moving

You don't need to wait for a research drug. Pacing, exercise, a cane, and suitable medicine may still help. Ask a clinician which choices fit your health. You'll need a cause before choosing the care.

Once the exam is done, QC Kinetix offers regenerative treatment options; these are non-surgical procedures that can start with blood drawn from you and prepared at the clinic. That care is sometimes called joint preservation. Here, that just means trying to keep your own joint useful. It isn't one special procedure or a promise to avoid surgery.

Severe daily limits can make surgery worth discussing

Some hips stay sore after careful non-surgical care. Trouble dressing, walking, or sleeping can make surgery worth a talk. An operation isn't a failure. Waiting isn't always the safer choice.

Ask what you could gain or risk by delaying surgery. Your health and X-ray both matter to that answer. So do the daily jobs your hip now stops. You don't have to try every clinic procedure first.

Sources

1. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

2. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection.

   Yazici Y, et al. — A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.. Clinical and experimental rheumatology, 2025. DOI: 10.55563/clinexprheumatol/hjt118.

3. The phase II trial of lorecivivint (SM04690), an intra-articular CLK2/DYRK1A inhibitor and Wnt-pathway modulator, is the reference for how a genuine disease-modifying osteoarthritis DRUG is developed - defined molecule, defined target, dose-ranging, radiographic endpoints - which is the standard against which an unstandardised autologous injectate should be read.

   Yazici Y, et al. — Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41315.

4. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.